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AbstrAct
Two-thirds of people aged ≥65 years have multi-morbidity. Multi-morbidity includes both 
physical and mental health conditions, as anxiety and depression, that almost invariably 
affect patients with multiple symptomatic chronic diseases.
Management of a patient with any of the chronic diseases that are part of multi-morbid-
ity is not just the management of that single index disease, but must include the active 
search and proper treatment of concomitant chronic diseases. The presence of concomitant 
chronic diseases should not alter the management of the index disease (e.g., chronic 
obstructive pulmonary disease [COPD]), and concomitant chronic diseases should be treat-
ed according to single diseases guidelines regardless of the presence of the index disease, 
obviously with careful consideration that this choice implies complex management, poly-
pharmacy and potential adverse effects. Preliminary management programs suggest that 
a holistic integrated approach might improve quality of life and reduce hospital admis-
sions and death in these multimorbid patients. (BRN Rev. 2017;3:247-66)
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IntroductIon
The improvement in socio-sanitary condi-
tions and of medicine and technology has 
increased dramatically the lifespan of the 
population, with a global median life expec-
tancy at birth for both sexes of 71.4 years and 
a median healthy life expectancy (HALE) of 
63.1 years1, suggesting that longer survival 
does not translate into longer healthy life but 
rather in several life years associated with 
frailty, disability, and multi-morbidity2-4.
The burden of noncommunicable diseases 
and issues in prevention, detection, and treat-
ment have been recently reviewed in the most 
prestigious medical journals2,3 and also in a 
specific topic on the guideline from The Na-
tional Institute for Health and Care Excel-
lence (NICE) organization5,6.
Multi-morbidity is related to frailty and dis-
ability and, in fact, these terms are often used 
interchangeably, whereas they represent three 
distinct clinical concepts, albeit not yet clear-
ly defined5-7.
FrAIlty
Frailty is defined as a condition characterized 
by reduced biological reserves which puts an 
individual at risk when facing minor stress-
ors. A minor stress puts a frail person at risk 
of falls and fluctuating disability which may 
increase care needs, hospital and care home 
admissions. Identifying someone as frail may 
be a useful way of identifying those people 
with multi-morbidity who would particularly 
benefit from optimizing medicines and treat-
ments.
dIsAbIlIty
Disability is defined as difficulty or depen-
dency in the execution of daily activities that 
are essential for independent living. As dis-
ability is considered a dynamic process, older 
people can recover to a less disabled or non- 
disabled state8,9.
MultI-MorbIdIty
Multi-morbidity is defined by the presence of 
two or more long-term chronic diseases in the 
same individual5,6,10. However, this definition 
was considered by the NICE commission too 
broad to be useful, as a very large number of 
people would have multi-morbidity defined 
as two or more long term conditions (e.g., 16-
58% of adults in the United Kingdom [UK]), 
but for many such people their multi-morbid-
ity will present them few problems in their 
life (e.g., someone with well-controlled asth-
ma and modest hyperdislipidaemia) or in 
theirhealthcare (e.g., type 2 diabetes, hyper-
tension and hay fever). Thus the NICE guide-
lines were targeted towards patients with 
multiple conditions that cause significant 
problems to everyday functioning or complex 
management of their care5,6. They preferred 
the term condition as it includes symptom 
complexes and/or management of major risk 
factors that are not necessarily classified as 
disease. In general, an approach to care that 
takes account of so defined multi-morbidity 
would better identify people for whom a 
multi-morbidity approach to care may be ap-
propriate5. This would include patients with 
physical and mental health problems who ex-
press difficulties in managing their condi-
tions and treatments, patients who already 
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require input from multiple services, particu-
larly if the addition of further services is be-
ing considered. Other potential indicators of 
these patients suggesting an increased bur-
den are prescription of multiple regular med-
icines, frequent use of health care resources, 
or frailty and disability as previously de-
scribed. 
According to one of the largest studies con-
ducted in about one third of the Scotland 
population (1,751,841 medical records), 42% of 
the population had at least one of the 40 con-
ditions counted, and 23% had multi-mor-
bidity, i.e., ≥ 2 conditions. Two-thirds of 
people aged ≥ 65 years had multi- morbidity, 
and 47% had ≥ 3 conditions. People living 
in the most deprived areas developed multi- 
morbidity 10-15 years before their more af-
fluent peers. In addition to a poorer quality 
of life, multi- morbidity is associated with high-
er mortality, polypharmacy and high treat-
ment burden, higher rates of adverse drug 
events, and much greater health services use 
including emergency hospital admissions. Multi- 
morbidity includes both physical and mental 
health conditions, as anxiety and depression, 
that almost invariably affect patients with mul-
tiple symptomatic chronic diseases11.
The relationship between frailty, disability 
and multi-morbidity can be summarized as 
in the attached flow-chart adapted from Vi-
llacampa-Fernández et al.4 (Fig. 1).
The most important diseases that contribute 
to multi-morbidity are reported in table 1, 
whereas the number of concomitant chronic 
diseases and their relationship with age are 
reported in figures 2 A and B.
Frailty
NCDs Multimorbidity
Disability
Health
Deficits
Adverse
Health
Figure 1. Flowchart of the system failure process. Circles represent inputs/outputs, rectangles represent clinical conditions, continuous 
lines represent direct effects, dotted lines represent indirect or secondary effects (reproduced with permission from P. Villacampa-
Fernandez et al.4)
NCDs: non-communicable diseases.
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The weight in term of prevalence and trend 
in mortality and disability adjusted life-year 
are reported in figures 2A and B (Table 1, 
Fig. 3A and B), from Barnett et al11.
NICE guidelines have been developed for the 
management of many individual diseases and 
conditions. The aim of this guideline is to 
inform patient and clinical decision-making 
and models of care for people with multi-mor-
bidity who would benefit from an individual 
approach because of high impact on their 
quality of life or functioning due to their con-
ditions or their treatments. Although this is a 
particular concern of generalists such as gen-
eral practitioners or geriatricians, the guide-
line is also relevant to specialists since many 
of the patients they care for will have other 
significant conditions.
PulMonAry AbnorMAlItIEs  
In MultIMorbId PAtIEnts
While the field of multi-morbidity has exploded 
in the last 15 years in term of epidemiologic 
studies and number of papers, the number 
of original studies on diagnosis, assessment of 
severity and more importantly management 
of multimorbid patients is almost non-exist-
ing, almost all studies being related to comor-
bidities of single index disease.
Thus, in this narrative review, after a general 
introduction on dyspnoea and exacerbations, 
we will summarize the results of studies re-
lated to single index non-pulmonary disease, 
with focus on COPD as the most frequent 
concomitant chronic diseases that has been 
examined most extensively in other chronic 
diseases12.
dysPnoEA
Dyspnoea is not only the cardinal symptom 
of COPD13,14 and of chronic heart failure15, but 
also a frequent symptom of several other 
chronic diseases that have been examined as 
part of multi-morbidity11, e.g., ischaemic heart 
diseases (IHC), atrial fibrillation, anaemia, 
chronic kidney diseases, chronic liver diseas-
es, obesity, malnutrition and cachexia, hypo-
thyroidism, asthma, interstitial lung diseases, 
depression just to mention some13,16. Also, 
some of the medications used to treat chron-
ic diseases may cause or worsen dyspnoea, 
e.g., beta-blockers (BB), angiotensin- converting 
enzyme (ACE) inhibitors, antidepressants.
Thus, dyspnoea is a frequent symptom of frail-
ty, disability and multi-morbidity, particular-
ly in the elderly, but is of course a very non-
specific symptom as it may be caused by a 
variety of different chronic diseases13,16.
The main cardiorespiratory and non-cardiore-
spiratory conditions associated with dyspnoea 
in the elderly have been recently reviewed 
and are summarized below17. They include:
– Respiratory Diseases
– Cardiovascular Diseases
– Musculoskeletal abnormalities
– Neuropsychological abnormalities
– Anaemia
– Reduced renal function
– Obesity or cachexia
– Medications
In respiratory diseases, respiratory impair-
ments decrease ventilatory capacity and may 
lead to dyspnoea at low exertional workloads. 
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Table 1. List of the 40 disease conditions included in multi-morbidity count (reproduced with permission from Barnett K11)
Condition Variable definition Mental/physical 
health condition
Prevalence 
(%)
Hypertension Read code ever recorded Physical 13.4
Depression Read code recorded in last 12 months OR ≥ 4 anti-depressant 
prescriptions (excluding low dose tricyclics) in last 12 months
Mental  8.2
Painful condition ≥ 4 prescription only medicine analgesic prescriptions in last 12 months 
OR ≥ 4 specified anti-epileptics in the absence of an epilepsy Read 
code in last 12 months
Physical  7.2
Asthma (currently treated) Read code ever recorded AND any prescription in last 12 months Physical  6.0
Coronary heart disease Read code ever recorded Physical  4.7
Treated dyspepsia ≥ 4 prescriptions in last 12 months BNF 0103% excluding antacids 
AND NOT (≥ 4 NSAIDS OR ≥ 4 aspirin/clopidogrel)
Physical  4.5
Diabetes Read code ever recorded Physical  4.3
Thyroid disorders Read code ever recorded Physical  4.1
Rheumatoid arthritis, other inflammatory 
polyarthropathies & systematic 
connective tissue disorders
Read code ever recorded Physical  3.4
Hearing loss Read code ever recorded Physical  3.4
Chronic obstructive pulmonary disease Read code ever recorded Physical  3.2
Anxiety & other neurotic, stress 
related & somatoform disorders
Read code in last 12 months OR ≥ 4 anxiolytic/hypnotic prescriptions 
in last 12 months OR ≥ 4 10/25 mg amitriptyline in last 12 months & do not 
meet the criteria for “Pain”
Mental  3.2
Irritable bowel syndrome Read code ever recorded OR ≥ 4 prescription only medicine 
antispasmodic prescription in last 12 months
Physical  3.0
New diagnosis of cancer in last five years Read code first recorded in last 5 years Physical  2.5
Alcohol problems Read code ever recorded Mental  2.4
Other psychoactive substance misuse Read code ever recorded Mental  2.4
Treated constipation ≥ 4 laxative prescriptions in last year Physical  2.2
Stroke & transient ischaemic attack Read code ever recorded Physical  2.1
Chronic kidney disease Read code ever recorded Physical  1.9
Diverticular disease of intestine Read code ever recorded Physical  1.9
Atrial fibrillation Read code ever recorded Physical  1.4
Peripheral vascular disease Read code ever recorded Physical  1.3
Heart failure Read code ever recorded Physical  1.1
Prostate disorders Read code ever recorded Physical  0.9
Glaucoma Read code ever recorded Physical  0.9
Epilepsy (currently treated) Read code ever recorded AND antiepileptic prescription in last 12 months Physical  0.8
Dementia Read code ever recorded Mental  0.7
Schizophrenia (and related non-organic 
psychosis) or bipolar disorder
Read code ever recorded/recorded in last 12 months (code dependent) 
OR Lithium prescribed in last 168 days
Mental  0.7
Psoriasis or eczema Read code ever recorded AND ≥4 related prescriptions in last 12 months 
(excluding simple emollients)
Physical  0.7
Inflammatory bowel disease Read code ever recorded Physical  0.6
Migraine ≥ 4 prescription only medicine anti-migraine prescriptions in last year Physical  0.6
(continued)
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In addition, dead space ventilation may be 
greater in individuals with respiratory condi-
tions (e.g., COPD), further exacerbating dys-
pnoea through greater ventilatory demand. 
Cardiovascular impairments decrease the de-
livery and distribution of oxygen to the ex-
ercising muscle, which reduces its aerobic 
capacity, leading to exercise-induced lactic 
acidosis at low exertional workloads. The sub-
sequent buffering of lactate by bicarbonate 
increases carbon dioxide flux to the lungs, 
increasing ventilatory demand and leading 
to dyspnoea.
Musculoskeletal impairments decrease oxygen 
use at the level of the exercising muscle, re-
ducing its aerobic capacity and leading to ex-
ercise-induced lactic acidosis at low exertional 
workloads. As discussed earlier, exercise-in-
duced lactic acidosis can lead to dyspnoea 
through an increase in ventilatory demand. 
Neuropsychological impairments may affect 
the experience of dyspnoea by altering the 
perception of breathing discomfort or by 
leading to a sedentary state that adversely 
affects the aerobic capacity of the exercising 
muscle.
Anaemia decreases arterial oxygen content 
and can thus lead to exertional dyspnoea as 
a consequence of a reduction in the delivery 
of oxygen to the exercising muscle. Anaemia 
may also exacerbate coexisting cardiorespira-
tory impairments. 
Impaired renal function may lead to dys-
pnoea as a result of high ventilatory demand 
from the bicarbonate buffering of an under-
lying metabolic acidosis. Chronic kidney dis-
ease may also exacerbate respiratory, cardio-
vascular, and musculoskeletal impairments. 
Obesity and weight loss may lead to sarco-
paenia and, in turn, to dyspnoea take out 
including as a result of impairments of the 
muscles of ambulation and breathing.
Finally, use of medications may also affect the 
experience of dyspnoea by altering the per-
ception of breathing discomfort or through 
adverse effects on respiratory, cardiovascular, 
and musculoskeletal function.
Table 1. List of the 40 disease conditions included in multi-morbidity count (reproduced with permission from Barnett K11) (continuation)
Condition Variable definition Mental/physical 
health condition
Prevalence 
(%)
Blindness & low vision Read code ever recorded Physical  0.5
Chronic sinusitis Read code ever recorded Physical  0.5
Learning disability Read code ever recorded Mental  0.3
Anorexia or bulimia Read code ever recorded Mental  0.3
Bronchiectasis Read code ever recorded Physical  0.2
Parkinson’s disease Read code ever recorded Physical  0.2
Multiple sclerosis Read code ever recorded Physical  0.2
Viral hepatitis Read code ever recorded Physical  0.1
Chronic liver disease Read code ever recorded Physical  0.1
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Heart faiture
Stroke/TIA
Atrial fibrillation
Goronary heart disease
Painful condition
Diabetes
COPD
Hypertensión
Cancer
Epilepsy
Asthma
Dementia
Anxietry
Schizophrenia/bipolar
Depression
0% 20% 40% 60% 80% 100%
Percentage of patients with each condition 
who have other conditions
+ 3 or more others
+ 2 others
This condition + 1 other
This condition only
3 9 7414
6 14 6218
7 13 6516
9 16 5619
13 21 4621
14 20 4719
18 19 4717
22 24 3519
23 21 3917
31 23 2916
48 20 2112
5 13 6418
7 17 5620
13 21 4621
23 22 3618
Figure 2a. Number of conditions experienced by patients with common, important diseases (reproduced with permission from Barnett K11).
COPD: chronic obstructive pulmonary disease; TIA: transient ischaemic attack.
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Figure 2b. Number of chronic disorders by age-group (reproduced with permission from Barnett K11).
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Figure 3a. Global deaths and global disability-adjusted life years (DALYs) due to noncommunicable diseases in 1990 and 2010. DALYs are 
the sum of years of life lost from premature death and years lived with disability (reproduced with permission from Hunter DJ 2).
Figure 3b. Declines in rates of death from major noncommunicable diseases in the United States, 1950 to 2010 (reproduced with permission 
from Hunter DJ 2).
COPD: chronic obstructive pulmonary disease.
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In a multivariable logistic regression model, 
a strong association with moderate to severe 
dyspnoea was found to be, in rank order, lung 
function, left ventricular ejection fraction, de-
pressive symptoms and obesity, whereas re-
spiratory muscle weakness, diastolic cardiac 
dysfunction, grip weakness, anxiety symp-
toms, and use of cardiovascular and psycho-
active medications had a minor effect17.
ExAcErbAtIons oF dysPnoEA
Exacerbations of COPD are still defined as 
acute events characterized by a worsening of 
the patient’s respiratory symptoms, particu-
larly dyspnoea, beyond day-to-day variation, 
leading to a change in medical treatment 
and/or hospitalization14. Patients with COPD 
frequently have almost invariably chronic co-
morbidities, and several of these comorbidi-
ties may also exacerbate (e.g., acute heart fail-
ure, myocardial infarction, atrial fibrillation, 
stroke, acute kidney failure), each of them 
contributing to the increased morbidity and 
mortality not only in patients with COPD but 
also in patients with any of the concomitant 
chronic diseases. Thus, even if by definition, 
acute exacerbations of COPD are considered 
a respiratory condition, with specific refer-
ence to dyspnoea and to the organs involved 
(airways and lung); in fact, the exacerbations 
of dyspnoea may also be caused by exacerba-
tion of concomitant chronic diseases (e.g., de-
compensated heart failure, arrhythmias and 
thromboembolisms), without even involving 
the airways and lung. The clinical manifes-
tations of decompensated heart failure, ar-
rhythmias, ischaemic heart disease (IHD), 
kidney failure, thromboembolism, anaemia, 
and even stroke and depression. Interestingly, 
depression is a very frequent component of 
multi-morbidity, creating a vicious circle with 
dyspnoea, so that the presence of anxiety and 
depression is associated with early admission 
to hospital in the course of a dyspnoea exac-
erbation because of a more intense perception 
of respiratory symptoms. The bottom line is 
that exacerbations of respiratory symptoms, 
and particularly dyspnoea, represent the com-
plex pathogenic interactions between COPD 
and exacerbation of various concomitant chron-
ic diseases forming the multi-morbidity, and 
this results in degrees of summing, overlap-
ping or mimicking of respiratory symptoms 
often diagnosed as COPD exacerbation only 
because the presenting patients are elderly 
and smokers or ex-smokers (Fig. 4)18. 
The first Global Initiative for Chronic Ob-
structive Lung Disease (GOLD) document 
that specifically introduced the important 
concept of COPD as pulmonary component 
of a systemic disease and concomitant chron-
ic diseases due to smoking and ageing is the 
2007 GOLD report19, that stated “Because COPD 
often develops in long-time smokers in middle age, 
patients often have a variety of other diseases re-
lated to either smoking or aging. COPD itself also 
has significant extrapulmonary (systemic) effects 
that lead to comorbid conditions. Thus, COPD 
should be managed with careful attention also paid 
to comorbidities and their effect on the patient’s 
quality of life. A careful differential diagnosis and 
comprehensive assessment of severity of comorbid 
conditions should be performed in every patient 
with chronic airflow limitation” and devotes a 
specific paragraph to search and manage-
ment of “comorbidities”19.
The concepts of systemic effect of inflamma-
tion in COPD20,21 and of COPD pulmonary 
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component of a multimorbid inflammatory 
disease22,23 summarized the evidence col-
lected in several clinical and epidemiologic 
studies that have been increasingly pub-
lished starting in 2000 and that culminated 
in pivotal articles in major medical jour-
nals2,24.
Although the lung is usually identified as the 
primary target organ, smoking greatly affects 
other organs as cigarette smoking exposure 
leads to generalized endothelial injury affect-
ing both the lungs and many other organs as 
the vessels, the heart and the kidney25,27, thus 
leading to coincident chronic injury to differ-
ent organs. It is possible that in patients with 
COPD, changes caused by or linked to COPD 
per se (such as hypoxaemia, chronic systemic 
inflammation, and increased oxidative stress 
levels) contribute to the progression of differ-
ent organ injury by increasing the severity of 
endothelial injury20,21.
The evolution of the main concepts of GOLD 
documents has been nicely reviewed recently 
in conjunction with the 20th anniversary of 
GOLD28. Regarding comorbidities, the main 
message of the most recent GOLD document14 
is that COPD often coexists with other chron-
ic diseases that may have a significant impact 
on prognosis. Some of these diseases arise 
independently of COPD, whereas others may 
Exacerbations of respiratory symptoms
in patients with COPD
Exacerbation of COPD
Airway and lung inflammation
Exacerbation of coexistent
non-respiratory diseases
Hypertension
Heart failure
Ischaemic heart disease
Pulmonary embolism
Stroke
Depression
Exacerbation of coexistent
respiratory diseases
Asthma
Pneumonia
Bronchiectasis
Interstitial lung diseases
Pneumothorax
Figure 4. Exacerbation of respiratory symptoms in patients with chronic obstructive pulmonary disease (COPD) may be caused by 
respiratory infections and/or pollutants that cause acute inflammation of the airways and lung. These acute events may be correctly 
defined as exacerbations of COPD, but only after excluding other contributing mechanisms. Exacerbation of respiratory symptoms in 
patients with COPD and no comorbidities may be caused by acute independent events (e.g., pneumonia, pneumothorax, acute ischaemic 
heart disease and arrhythmias). These acute events should not be defined as exacerbations of COPD, but rather exacerbations of 
respiratory symptoms in patients with COPD, followed by a description of the cause(s) (reproduced with permission of the ERS 
©: European Respiratory Journal Apr 2013, 41 (4) 993-995; DOI: 10.1183/09031936.0018081218).
N
o
 p
ar
t 
o
f 
th
is
 p
u
b
lic
at
io
n
 m
ay
 b
e 
re
p
ro
d
u
ce
d
 o
r 
p
h
o
to
co
p
yi
n
g
 w
it
h
o
u
t 
th
e 
p
ri
o
r 
w
ri
tt
en
 p
er
m
is
si
o
n
  o
f 
th
e 
p
u
b
lis
h
er
. 
 
©
 P
er
m
an
ye
r 
Pu
b
lic
at
io
n
s 
20
17
BARCELONA
RESPIRATORY
NETWORK
Collaborative research
257
Bianca Beghé et al: coPd in the Multimorbid Elderly
be causally related, either with shared risk 
factors (e.g., ageing, smoking, inactivity, pre-
maturity at birth, early respiratory infections), 
or by the simple concept that the presence of 
one chronic disease component of the multi- 
morbidity may increase the risk or the sever-
ity of the other. The important message is 
that the management of the patient with 
COPD is not just the management of COPD, 
but must include identification and treatment 
of other concomitant chronic diseases. In 
particular, the recommendation is that the 
presence of comorbidities should not alter 
COPD treatment, and that these other con-
comitant chronic diseases should be treated 
according to single diseases guidelines re-
gardless of the presence of COPD, but con-
sidering that the treatment of a patient with 
COPD is part of a multi-morbidity care plan, 
and thus that attention should be directed to 
ensure simplicity of treatment and minimize 
polypharmacy.
The most frequent chronic diseases that are 
increased and have an impact on severity and 
prognosis in patients with COPD are listed in 
table 2. 
The prevalence and impact of these chronic 
conditions have been recently reviewed both 
in the GOLD document14, and in several re-
view articles27,29-34 to which we refer.
All documents underline the concept that 
concomitant chronic diseases are largely mis-
diagnosed or undiagnosed and thus untreat-
ed in COPD patients. A concept that was first-
ly reported for congestive heart failure (CHF) 
(80% undiagnosed CHF in COPD) by Rutten 
et al35 more than 10 years ago, and recently 
re-addressed in review articles36,37. 
The prevalence of the most representative 
chronic diseases found in patients with COPD 
when properly and actively searched is re-
ported in figure 538.
coPd In PAtIEnts wIth othEr 
chronIc dIsEAsEs 
While the prevalence and impact of concomi-
tant chronic diseases in COPD have been ex-
tensively examined and described, the prev-
alence and impact of COPD in other chronic 
Table 2. Most frequent chronic diseases that are increased 
in chronic obstructive pulmonary disease (COPD) and have an 
impact on severity and prognosis in patients with COPD.
Cardiovascular 
Diseases
Chronic heart failure
Ischaemic heart diseases
Arrhythmias
Peripheral artery disease
Stroke and transient cerebrovascular 
ischemia
Thromboembolism
Chronic respiratory 
diseases
Asthma
Bronchiectasis
Obstructive sleep disorders
Lung cancer
Interstitial lung diseases
Pulmonary hypertension
Tuberculosis
Human immunodeficiency virus (HIV)
Metabolic diseases
Metabolic syndrome
0besity
Nutritional disorders
Central Nervous 
system
Anxiety and depression
Psychiatric diseases
Cognitive impairment.  
Degenerative disorders
Endocrine diseases
Diabetes
Osteoporosis
Hypothyroidism
Gastrointestinal 
Diseases
Gastroesophageal reflux
Inflammatory bowel diseases
Chronic liver diseases
Miscellaneous
Chronic kidney diseases
Anaemia
Psoriasis
N
o
 p
ar
t 
o
f 
th
is
 p
u
b
lic
at
io
n
 m
ay
 b
e 
re
p
ro
d
u
ce
d
 o
r 
p
h
o
to
co
p
yi
n
g
 w
it
h
o
u
t 
th
e 
p
ri
o
r 
w
ri
tt
en
 p
er
m
is
si
o
n
  o
f 
th
e 
p
u
b
lis
h
er
. 
 
©
 P
er
m
an
ye
r 
Pu
b
lic
at
io
n
s 
20
17
BARCELONA
RESPIRATORY
NETWORK
Collaborative research
258
BRN Rev. 2017;3
conditions that are part of multi-morbidity 
have been less investigated. Unfortunately, no 
randomized clinical study has been conduct-
ed in patients with any of the following con-
comitant chronic diseases comparing patients 
with or without COPD or the concomitant 
chronic disease. 
cArdIovAsculAr dIsEAsEs
Because of the potential adverse effect of car-
diovascular drugs, and particularly the BB, 
the prevalence and impact of COPD has been 
more frequently investigated in cardiovascu-
lar diseases33,39.
hEArt FAIlurE
COPD and CHF commonly coexist in clinical 
practice, the prevalence of COPD among HF 
ranging from 12 to 40%33. Apart from the 
challenging questions related to diagnosis 
and assessment of severity linked to overlap 
of common risk factors, symptoms and clini-
cal manifestations14,15,33.
The presence of COPD in HF with both re-
duced and preserved ejection fraction increases 
burden of comorbidities, longer hospitaliza-
tions, underutilization of evidence-based med-
icine, and increased mortality40.
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Figure 5. Prevalence of actively searched concomitant chronic diseases in patients with chronic obstructive pulmonary disease (COPD) 
referred to a rehabilitation centre (reprinted with permission of the American Thoracic Society. Copyright © 2017 American Thoracic 
Societyfrom Vanfleteren LE38).
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A major focus of interest has been that key 
drugs for the management of HF, that the key 
drugs used to treat HF, while reduce hospi-
talizations, morbidity and mortaslity, might 
have piotential side-effects in patients with 
HF and COPD. Most studies have focused not 
only on BB, but also on ACE inhibitors, and 
aldosterone antagonists. The bottom line of all 
these studies, summarized in the most recent 
HF guidelines, are that all drugs required for 
the treatment of HF are safe and effective in 
patients with HF and COPD, the only excep-
tion being BB in patients with concomitant 
COPD and asthma15. This is particularly true 
for patients with HF with reduced ejection 
fraction39, whereas it remains to be properly 
investigated for the 50% of patients with HF 
and preserved ejections fraction who are treat-
ed like the former but without any evidence 
of efficacy and safety15.
Regarding efficacy, there are fundamental 
differences between the aims and efficacy of 
pharmacologic treatments of HF and COPD, 
for HF being mainly improvement of survival 
and quality of life, and reduction of hospital-
izations15, for COPD mainly improvement of 
symptoms and quality of life, and reduction 
of exacerbations, without any effect (apart from 
oxygen and lung surgery in selected patients) 
on mortality and progression of disease14.
IschAEMIc hEArt dIsEAsE
Multi-morbidity is increasingly prevalent 
among older adults presenting with acute myo-
cardial infarction, and includes both cardiovas-
cular (CV) (HF, hypertension, and arrhythmias) 
and non-CV (anaemia, chronic kidney dis-
ease, and depression) conditions. Hospital 
mortality and length of stay increase in a 
dose-dependent fashion with the number of 
CV and non-CV comorbidities41. 
The prevalence of COPD in patients with es-
tablished chronic IHD ranges from 8 to 30%33, 
and once again it is largely (> 80%) undiag-
nosed42.
Patients with IHD and COPD (up to 30%) 
undergoing percutaneous coronary interven-
tions or bypass, have at 5 years follow-up a 
10-fold increased mortality (31% versus 3.1%), 
a 2-fold increased risk of revascularization 
(40% versus 20%), and > 6-fold increased 
risk of re-hospitalization due to HF (25% 
versus 4%)43.
AtrIAl FIbrIllAtIon
Atrial fibrillation (AF) is the most common 
supraventricular arrhythmia in the general 
population and in patients with COPD as 
well. The prevalence of COPD in patients 
with AF ranges around 10 to 15%, reaching 
23.2% in patients older than 65 years and de-
pending on the population examined (Table 
E3 in Roversi et al.33).
Evidence on patients with both diseases is 
limited and focuses mainly on the prognos-
tic impact of coexisting COPD in patients 
with AF, revealing a significant association 
with hospital admissions and all-cause mor-
tality44. Concurrent COPD is a negative prog-
nostic factor for AF progression from parox-
ysmal AF to persistent AF, immediate and 
long-term success of cardioversion, and re-
currence of atrial tachyarrhythmia after cath-
eter ablation.
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coPd In coMPlEx 
cArdIovAsculAr PAtIEnts 
In clinical practice, complex CV patients (e.g., 
HF, IHD, and AF in the same patients) are com-
mon. However, when HF, IHD, or AF are con-
sidered in the medical literature, each disease 
is usually analyzed separately or as a global 
entity under the rubric of “cardiovascular co-
morbidities”. Therefore, data on the relation-
ship between the “complex cardiac patient” 
and COPD is scarce. Given the clinical rele-
vance of the topic, there is a pressing need for 
high-quality data on how best to diagnose, 
manage, and educate these patients.
strokE And trAnsIEnt 
IschAEMIc AttAcks
Cerebral small vessel disease and accumula-
tion of brain pathology associate with cogni-
tive decline and can lead to clinical outcomes, 
such as stroke, transient ischaemic attacks 
(TIA) and dementia. COPD is a common re-
spiratory disease among elderly. While there 
is clinical and epidemiologic evidence of ce-
rebral small vessel disease, stroke, TIAs, and 
(vascular) cognitive impairment in patients 
with COPD45,46, literature is very scarce on 
the presence of lung function abnormali-
ties and/or COPD in patients with stroke or 
TIA, and/or dementia. Patients with stroke 
have several concomitant chronic diseases, 
and > 20% have COPD47. One interesting 
study hypothesized that lower respiratory 
function may increase the risk for small-ves-
sel disease by lowering oxygen supply to the 
brain, and that lower respiratory function 
increases inflammatory responses in blood 
vessels, which may lead to atherosclerosis. 
Albeit limited to women, the 26-year fol-
low-up up study found that mid-life respira-
tory function and white matter lesions and 
lacunar infarcts in elderly women were relat-
ed to lower midlife respiratory function48.
PErIPhErAl ArtEry  
dIsEAsE
A significant proportion of patients with COPD 
(8.8%) have peripheral artery disease, a preva-
lence that is higher than the prevalence in con-
trol subjects without COPD. Peripheral artery 
disease is associated with a clinically relevant 
reduction in functional capacity and health 
status49. Limited is the literature on the prev-
alence of COPD in patients with peripheral 
artery disease. However, COPD, coronary ar-
tery disease, and peripheral artery disease, 
when coexisting in the same patient, are pos-
itively associated with the presence of ab-
dominal aortic aneurysm (AAA) and increase 
the risk of its rupture50.
throMboEMbolIsM
While the risk of thromboembolism and in 
particular of pulmonary embolism is increased 
in patients with stable COPD51, the size of this 
risk is variable in stable conditions52, but it 
increases during exacerbations of COPD53-55 
(Fig. 6). 
By contrast, interestingly, the prevalence of 
COPD in patients followed after a confirmed 
episode of venous thromboembolism is rela-
tively low (< 10%), and these patients are not 
at increased risk of future recurrences or 
death56.
N
o
 p
ar
t 
o
f 
th
is
 p
u
b
lic
at
io
n
 m
ay
 b
e 
re
p
ro
d
u
ce
d
 o
r 
p
h
o
to
co
p
yi
n
g
 w
it
h
o
u
t 
th
e 
p
ri
o
r 
w
ri
tt
en
 p
er
m
is
si
o
n
  o
f 
th
e 
p
u
b
lis
h
er
. 
 
©
 P
er
m
an
ye
r 
Pu
b
lic
at
io
n
s 
20
17
BARCELONA
RESPIRATORY
NETWORK
Collaborative research
261
Bianca Beghé et al: coPd in the Multimorbid Elderly
chronIc rEsPIrAtory dIsEAsEs
The prevalence and impact of airflow limita-
tion and/or COPD has been extensively stud-
ied and reviewed in asthma and obstructive 
sleep disorders14,57,58, bronchiectasis59,60, lung 
cancer14,61, interstitial lung diseases and pul-
monary hypertension62,63, tuberculosis64, and 
human immunodeficiency virus (HIV)65, and 
will not be addressed in this review.
MEtAbolIc dIsEAsEs
Metabolic syndrome is increased in over-
weight or obese COPD patients compared 
to matched control, and is associated with 
increased risk of morbidity and mortality 
with consequent increased risks linked to 
the concomitant chronic diseases linked to 
metabolic syndrome66-68. Even if little is known 
about the prevalence and impact of COPD in 
patients with the metabolic syndrome and/or 
obesity, because lung function is seldom mea-
sured in these patients, the observation that 
obese patients with mild COPD had more co-
morbid conditions suggesting that obesity and 
COPD may be a risk69,70. 
Indeed, there are potential mechanisms of 
interaction between COPD and the compo-
nents of the metabolic syndrome, e.g., arterial 
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Figure 6. The prevalence of pulmonary embolism (PE) in chronic obstructive pulmonary disease (COPD) exacerbations across studies 
(reproduced with permission of the ERS ©: Franssen F, Vanfleteren L54).
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hypertension71, diabetes72, hyperdyslipidemia73, 
and overweight/obesity. All this suggest that 
the coexistence of COPD and metabolic syn-
drome or some of its components may in-
crease the severity of its clinical manifesta-
tions and future risks71,72.
Low body mass index and reduced and ab-
normal diaphragmatic and skeletal mass that 
are associated with lower exercise capacity 
and higher mortality in patients with COPD 
may represent either a risk factor or a system-
ic effect of COPD20. The effects of nutritional 
interventions and/or rehabilitation may coun-
teract this vicious circle74-76.
chronIc nEurologIcAl 
dIsordErs
Depression and anxiety have been extensively 
reported as clinical manifestations of chronic 
diseases77,78, but were never properly investi-
gated mechanistically and more importantly, 
COPD has never been adequately investigat-
ed in patients affected by or treated because 
of anxiety and/or depression. Similarly, no 
proper studies have been conducted in the 
field of impact of COPD on chronic neurolog-
ical degenerative disorders such as Alzhei-
mer, Parkinson, and dementia, all potentially 
linked to smoking79, that represent a very im-
portant component of the multimorbid chron-
ic elderly patient.
EndocrInE dIsEAsEs
Patients with both type 1 and type 2 diabe-
tes have reduced lung function independent-
ly from other risk factors and particularly 
smoking80. The relationship between type 2 
diabetes and COPD is still unclear but com-
mon mechanisms may create vicious circles72.
While it is well known that osteoporosis is close-
ly associated with COPD, and that osteoporosis 
and osteoporotic fractures are common in 
COPD patients, a recent retrospective study 
conducted in newly-diagnosed male osteopo-
rotics found that COPD may actually repre-
sent the leading cause of secondary osteopo-
rosis, more frequent than glucocorticoid use 
or hypogonadism, and osteoporosis-associat-
ed fractures may further deteriorate pulmo-
nary function and thereby impair activities of 
daily life (ADL) of COPD patients81. Thus, the 
two diseases will form a vicious cycle that 
causes significant burdens on the patients. 
Osteoporosis in COPD patients and vice-ver-
sa are however largely underdiagnosed and 
undertreated81.
Albeit both hypothyroidism82, and hyperthy-
roidism83 may be associated with exertional 
dyspnoea, and fatigue can be the presenting 
complaint, their relationship with COPD has 
not been investigated.
gAstroIntEstInAl  
dIsEAsEs
The most frequently investigated gastrointes-
tinal disease in patients with COPD has been 
gastroesophageal reflux, that has been shown 
in several studies to represent a significant 
risk factor for symptom severity and exacer-
bations84. By contrast, almost no study has 
been conducted looking at COPD in patients 
with gastroesophageal reflux.
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Airway diseases are the most commonly de-
scribed lung manifestations of inflammatory 
bowel disease (IBD). However, the similari-
ties in disease pathogenesis and the sharing 
of important environmental risk factors and 
genetic susceptibility suggest that there is a 
complex interplay between IBD and airway 
diseases85.
Only very recently associations between COPD 
and some chronic liver diseases, in particular 
non-alcoholic fatty liver disease (NAFLD)86,87, 
and viral hepathitis have been reposted88.
chronIc kIdnEy dIsEAsEs
The coexistence of chronic kidney disease and 
COPD has been recently reviewed30. The patho-
physiology of the two conditions had been 
previously extensively addressed in patients 
with respiratory failure89, whereas the effects 
of age and long-term smoking on renal and 
pulmonary function has not. One potential 
vicious circle between chronic kidney disease 
and COPD is cachexia and/or sarcopenia90.
MIscEllAnEous
Other frequent chronic diseases that represent 
important component of chronic multi-mor-
bidity in the elderly have been associated with 
COPD, even is the cause-effect relationship 
has not been established. Among these diseas-
es it is worth mentioning psoriasis91 and rheu-
matoid arthritis92, possibly because in both 
smoking represents a major risk factor, and 
thus patients who develop these diseases ear-
lier in life may be at increased risk of devel-
oping COPD later in life.
conclusIons
Multi-morbidity affects more than two thirds 
2/3 of elderly subjects and includes both 
physical and mental health conditions, as anx-
iety and depression, that almost invariably 
reduce the quality of life of these patients.
The management of a patient with any of the 
chronic diseases that are part of multi-mor-
bidity is not just the management of that sin-
gle presenting index disease, but must include 
the active search and proper treatment of con-
comitant chronic diseases. The presence of 
concomitant chronic diseases should not alter 
the management of the index disease, and 
concomitant chronic disease should be treat-
ed according to single disease guidelines re-
gardless of the presence of the index disease, 
obviously with careful consideration that this 
choice implies complex management, poly-
pharmacy and potential adverse effects.
Ongoing multidisciplinary hospital and home 
base management programs suggest that a 
holistic integrated approach might improve 
quality of life and reduce admissions and du-
ration of stay at the hospital, and possibly 
death in these multimorbid patients93,94. 
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